GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.
GlaxoSmithKline Pharmaceuticals Dividend Announcement
• GlaxoSmithKline Pharmaceuticals announced a semi annually dividend of ₹12.00 per ordinary share which will be made payable on 2024-11-28. Ex dividend date: 2024-11-07
• GlaxoSmithKline Pharmaceuticals annual dividend for 2024 was ₹44.00
• GlaxoSmithKline Pharmaceuticals annual dividend for 2023 was ₹32.00
• GlaxoSmithKline Pharmaceuticals's trailing twelve-month (TTM) dividend yield is 1.89%
• GlaxoSmithKline Pharmaceuticals's dividend growth over the last five years (2018-2023) was -1.78% year
• GlaxoSmithKline Pharmaceuticals's dividend growth over the last ten years (2013-2023) was -4.36% year
GlaxoSmithKline Pharmaceuticals Dividend History
Ex-Div date | Dividend amount | Dividend type | Pay date |
---|---|---|---|
2024-11-07 | ₹12.00 | semi annually | 2024-11-28 |
2024-05-31 | ₹32.00 | semi annually | 2024-07-28 |
2023-06-30 | ₹32.00 | semi annually | 2023-08-25 |
2022-07-07 | ₹60.00 | semi annually | 2022-08-25 |
2021-07-19 | ₹30.00 | semi annually | 2021-08-26 |
2020-07-17 | ₹20.00 | semi annually | 2020-08-26 |
2019-07-11 | ₹20.00 | semi annually | 2019-08-21 |
2018-07-13 | ₹35.00 | semi annually | 2018-08-23 |
2017-07-14 | ₹30.00 | semi annually | 2017-08-24 |
2016-07-15 | ₹50.00 | semi annually | 2016-08-27 |
2015-07-23 | ₹62.50 | semi annually | 2015-08-30 |
2014-04-03 | ₹50.00 | semi annually | 2014-05-17 |
2013-04-04 | ₹50.00 | semi annually | 2013-04-17 |
GlaxoSmithKline Pharmaceuticals Dividend per year
GlaxoSmithKline Pharmaceuticals Dividend growth
GlaxoSmithKline Pharmaceuticals Dividend Yield
GlaxoSmithKline Pharmaceuticals current trailing twelve-month (TTM) dividend yield is 1.89%. Interested in purchasing GlaxoSmithKline Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:
GlaxoSmithKline Pharmaceuticals Financial Ratios
GlaxoSmithKline Pharmaceuticals Dividend FAQ
Other factors to consider when evaluating GlaxoSmithKline Pharmaceuticals as a dividend stock include its dividend yield, dividend growth, payout ratio, and the sustainability of its dividend payments given its earnings and cash flow. These factors can provide insight into the company's ability to maintain or increase its dividend in the future.
Place an order: Use the brokerage's trading platform to place an order to buy GlaxoSmithKline Pharmaceuticals stock.
Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.
1. Determination of Dividend: GlaxoSmithKline Pharmaceuticals's board of directors reviews the company's financial performance, cash flow, future investment needs, and other relevant factors to determine the amount and timing of dividend payments.
2. Dividend Declaration: Once the board approves a dividend, GlaxoSmithKline Pharmaceuticals publicly announces the dividend amount, currency, and the ex-dividend date. The ex-dividend date is the date on or after which the buyer of the stock will not be eligible to receive the upcoming dividend payment.
3. Record Date: The record date is the date on which the company checks its records to identify shareholders who are eligible to receive the dividend. Only shareholders on record as of this date will receive the dividend.
4. Payment Date: On the designated payment date, GlaxoSmithKline Pharmaceuticals distributes the dividend to eligible shareholders. The dividend is usually paid in the form of cash directly into the shareholder's brokerage account or through other designated payment methods.
5. Tax Implications: Dividends received from GlaxoSmithKline Pharmaceuticals are generally taxable as income. Shareholders may need to report dividend income on their tax returns and pay applicable taxes according to their jurisdiction's tax regulations.
1. Record Date: GlaxoSmithKline Pharmaceuticals sets a record date, which is the date on which the company checks its records to determine the eligible shareholders. Only those who are shareholders on record as of this date will receive the dividend.
2. Payment Date: On the designated payment date, GlaxoSmithKline Pharmaceuticals distributes the dividend to eligible shareholders. The payment is usually made electronically, directly into the shareholder's brokerage account or bank account.
3. Currency: GlaxoSmithKline Pharmaceuticals declares the currency in which the dividend will be paid. Depending on the shareholder's location and the currency election made by the shareholder, the dividend will be converted to the appropriate currency during the payment process.
To assess the safety of GlaxoSmithKline Pharmaceuticals's dividend, it is crucial to analyze the company's financial health, debt levels, cash flow generation, and ability to sustain dividend payments over the long term. Additionally, monitoring the company's future earnings, cash flow projections, and management's commitment to dividend policies can provide valuable insights.
It is recommended to review GlaxoSmithKline Pharmaceuticals's financial reports, official announcements, and consult with financial advisors or experts who have access to the most current and comprehensive information about the company's financial situation.